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2Abstract
In this paper the costs and benefits associated  with DNA-diagnosis of individuals who are at
risk of a child with a monogenic disease  and who seek genetic counselling because of their
reproductive plans are predicted under various assumptions using a mathematical model. Four
monogenic diseases have been considered: cystic fibrosis, Duchenne muscular dystrophy,
myotonic dystrophy and fragile X syndrome. Counselling (triggered by prior information) on the
basis of DNA-diagnosis is compared to the situation that only risk evaluation based on pedigree
analysis is possible. The results show for each disease that with DNA-diagnosis couples can be
more confident in choosing (further) offspring leading to the birth of more healthy children while
the number of affected children is reduced. The costs minus savings within the health care sector
depend on the prior risks and to the future burden of the monogenic illness considered. DNA-
diagnosis of relative “low” prior risks of a child with CF (e.g. 1:180, 1:240 and 1:480) leads to
costs in stead of savings. For higher prior risks of CF and for the three other diseases DNA-
diagnosis induces considerable savings. This result remains valid when assumptions regarding
behaviour regarding reproduction and receiving DNA-diagnosis under different circumstances
are varied.
3Introduction
DNA-diagnosis has become an important part of genetic counselling as DNA-analyses are
being applied to a growing number of monogenic diseases for carrier screening and prenatal
diagnosis. Seven genetic centres perform DNA-diagnosis in The Netherlands. The Health
Insurance Executive Board initiated an economic appraisal study in 1992 to support a decision
about reimbursement and about licensing of these facilities, which we report on here.
This study focuses on the costs and benefits associated with DNA-diagnosis of individuals who
are at risk of a child with a monogenic disease and who seek genetic counselling because of
their reproductive plans. 'At risk' in this research means that couples who ask for information
are related to an affected person. This complies with the indications for genetic counselling of
monogenic hereditary diseases in the Netherlands. In genetic counselling there are two situations
to which DNA-diagnosis may apply: (i) when a person at risk wants to know if he or she is a
carrier of a genetic disease (carrier screening or presymptomatic diagnosis) and (ii) when a
pregnant couple wants to know if the fetus is disadvantaged (prenatal diagnosis). Both
applications are considered here.
The costs and benefits of DNA-diagnosis are predicted under various assumptions on
reproduction decisions using a mathematical model (figure 1) and are represented for four
monogenic diseases: cystic fibrosis, Duchenne muscular dystrophy, myotonic dystrophy and
fragile X syndrome.
4Methods
Alternatives
In cost-effectiveness analysis, the costs and benefits of a defined health care programme are
compared with costs and benefits of one or more alternatives. This study compares DNA-
diagnosis with the situation that only risk evaluation based on pedigree analysis is possible. As
the situation with DNA-diagnosis is technically superior to other diagnostic tests the proposed
comparison is the most relevant for demonstrating the benefits of genetic counselling in general
and DNA-diagnosis in particular. In both situations retrospective counselling (triggered by prior
information) is the policy under consideration here. This means that genetic counselling is only
provided after the birth of the first affected child in a family (or after the identification of an index
patient in a family). The availability of DNA-diagnosis may prevent the parents from having a
second affected child and provides the possibility of having at least one other healthy child by
making use of prenatal diagnosis. Other relatives of an affected child may also be screened if
such information is useful (e.g. in relation to a reproductive decision).
[here about figure 1]
Decisions on reproduction and associated chances
A model (figure 1) is used incorporating assumptions about several decisions on reproduction
and about associated chances of healthy progeny. The decisions on reproduction are derived
from published research or expert opinion. Almost no disease-specific information about these
decisions was available, so for all diseases, except cystic fibrosis, baseline assumptions are used
to measure the costs and benefits of the compared interventions. The successive assumptions
regarding reproductive decisions  and the references to the literature are mentioned in table 1.
Furthermore a number of probabilities regarding incidence of illness are incorporated in the
model; risk of infertility: 10% [1], risk of induced abortion after chorionic-villus sampling: 1%
5[2] and conditional risks of an affected or a healthy child.
[table 1]
Effects
The objective of genetic counselling, according to the definition of the WHO, is to help people
with a genetic disadvantage to live and to reproduce as normally as possible [13]. This means
that DNA-diagnosis for retrospective genetic counselling enables couples at risk  to take
informed decisions about (further) reproduction. In this way they may complete their families
with minimal risk. A traditional cost-effectiveness analysis, where costs per life year gained or
per QALY (quality adjusted life year) gained are measured, is not appropriate here since the
different dimensions in which benefits can be expressed, cannot be aggregated to one unique
summary outcome measure. The effects relate to information about genetic risks available to a
family, a better chance of healthy posterity and, on the negative side, a higher risk of a
terminated pregnancy. Thus the effects in this analysis are presented as the differences between
the situation with DNA-diagnosis and the situation that only pedigree analysis is possible as
regards the numbers of:
- couples choosing (further) offspring and getting pregnant.
- healthy children
- affected children
- terminated pregnancies
6Costs
Only the costs within the health care system, shown in table 2,  are considered here.
The costs of diagnosis (carrier screening and prenatal diagnosis) are based on the average costs
of a test in 4 major DNA-laboratories in the Netherlands.  The costs of deliveries and the costs
of selective or induced abortion are based on Dutch tariffs and the costs of treatment of the
monogenic diseases are based on global "burden of illness" studies or published research [14].
Expert-panels provided information on the profile of resource use in the treatment of the other
three diseases, and cost studies were performed to estimate the relevant unit costs of these
resource-use items. The total burden of illness was calculated by multiplying the volumes of used
resources with the unit costs.
Table 2 shows the estimated life time cost and the discounted costs for each disease. To allow
comparison of the burden of illness across diseases and to set this against the investment in
DNA-diagnosis, the flow of costs over time has to be expressed in a total amount representing
the present value of that flow. This is done by discounting costs in later periods using a discount
rate of 5%.
[here about table 2]
Results
Effects
Table 3  shows the effects of DNA-diagnosis for the selected illnesses in distinct risk groups.
These effects are the result of calculations based on the mathematic model shown in figure 1.
The effects are calculated for each disease in a group of 100 couples that consult a genetic
counsellor. As an example we will explain how these effects are calculated in case of CF. It is
7assumed that couples already have an affected child. In the situation that no form of carrier or
prenatal diagnosis is available 30% of parents at risk choose further offspring, the risk of a CF
child being 25%. This results in: 30 pregnancies, 7.5 affected children  and 22.5 healthy children
per 100 consulting couples. In the situation that DNA diagnosis is available 85% of the carriers
chooses further offspring, 90% chooses to perform prenatal diagnosis and 99% of the couples
chooses to terminate the pregnancy when the child is affected. Results: 85 pregnancies, 2.3
affected children, 63.2 healthy children and 19.5 terminated pregnancies (including 1% induced
abortions after chorionic-villus sampling) per 100 consulting couples. The comparison of the
two above mentioned  situations results in +55 pregnancies, +40.7 healthy children, -5.2
affected children and +19.5 terminated pregnancies as effects of DNA-diagnosis for 100
consulting couples.
[here about table 3]
In table 4 the effects per disease with a specific distribution of prior risks are shown.
[here about table 4]
The results for every individual disease are discussed below.
Cystic fibrosis
Cystic fibrosis (CF) is a severely debilitating chronic disease and causes a short life expectancy.
In families where a CF mutation is already known the mutation can definitely be identified or
excluded. Analysis of the ten most frequent mutations identifies 85% of all CF mutations [15].
The results show that with DNA-diagnosis couples in all risk categories (parents, man or
woman is: sibling, uncle/aunt, nephew/niece) can be more confident in choosing (further)
offspring, leading to the birth of more healthy children while the number of affected children can
be reduced.
8Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a lethal, recessive, X-linked neuromuscular disease.
DNA-diagnosis can identify or exclude a DMD mutation in 96.5% of female carriers or male
fetuses in families where the mutation is already known (pers. comm. Dr. B. Bakker, 1994).
The other 3.5% of the female carriers or male fetuses in these families have a risk of 1:2 for a
DMD mutation. The results of DNA-diagnosis are again calculated for four risk groups of 100
couples related to a DMD patient (woman is: mother and sister, mother, sibling, niece). Also
here similar positive results can be reported as in the case of cystic fibrosis.
Myotonic dystrophy
Myotonic dystrophy (DM) is an autosomal dominant disorder and is generally considered as a
disease of adult life or adolescence. The patients’ illness is more severe when the clinical
symptoms are presented at an earlier age [16]. The congenital variant is the most severe form of
MD and is only seen in the offspring of mothers who have the adult variant of DM [17]. A
combination of mutation analysis, marker analysis and clinical symptoms identifies or excludes
DM defenitely [18]. This study only takes into account the congenital form of DM (CDM) and
is based on calculations of two groups of 100 consultands at risk of a CDM child (women is
DM patient and mother of CDM child, women is DM patient). Therefore, the true effects and
savings taking into account also the positive effects as a consequence of minor DM disorders
will be higher than reported here. Here the number of affected children avoided is higher but at
the cost of more terminated pregnancies, because the two risk groups that are analysed have
larger prior risks of an affected (CDM) child than the analysed risk groups of CF and DMD.
Fragile X syndrome
Fragile X syndrome (fra(X)) is the most frequent hereditary form of mental retardation. The
mutation in men always results in severe mental retardation, as against ranging from completely
normal to severely retarded in women. DNA-diagnosis can definitely identify or exclude the
9fra(X) mutation [19, 20]. Costs and effect measurement in this analysis is limited to the risk of a
son with the fra(X) (lower bound estimate of positive effects) and is done for two groups of
100 couples with  prior risks of 45% and 22.5% of a son with the fra(X) (woman has son with
fra(X), woman is sister of fra(X) patient. Also here positive effects of the use of DNA-diagnosis
can be reported.
Costs
Table 5 shows the costs minus savings of the four diseases. The costs minus savings relate
strongly to the prior risks and to the burden of illness. DNA-diagnosis of relative "low' prior
risks of a child with CF (e.g. 1:180, 1:240 and 1:480 or the prior risk of a Cf child in case one
of the parents is a sibling, an aunt/uncle or nephew/niece, respectively of a CF child) leads to
costs in stead of savings. For all other risks groups, DNA-diagnosis induces considerable
savings.
[here about table 5]
Sensitivity-analysis
A univariate sensitivity analysis was done by varying subsequently all base line assumptions. The
results per disease with a specific distribution of prior risks (like in table 4) are presented in
table 6.
Under various assumptions regarding the choice for reproduction when no DNA-diagnosis is
available and the choice for prenatal diagnosis the effects of DNA-diagnosis in CF couples
remain positive. Only when sixty percent of the couples, with a 1 in 4 risk at a child with CF,
uses prenatal diagnosis, there will be a slight increase in the number of births of affected children
in a group of 100 consultants and consequently additional costs of DFL 12.000 per consulting
couple instead of savings. When seventy percent, or more, of these couples at risk makes use of
10
prenatal diagnosis the number of affected children will decrease. In the sensitivity analysis for
DMD, DM and fra(X) the positive effects and savings of the base line estimates do not change
into any negative consequences.
[here about table 6]
Also when other assumptions are varied (use of DNA-diagnosis 60-100%; further offspring
with DNA-diagnosis 60-100%; sensitivity of carrier diagnosis 0.9 - 1.0; costs of diagnosis DFL
500 - 2,500; costs of illness DFL 250,000 - 2,500,000) the effects of DNA-diagnosis remain
positive.
Discussion
The effects of DNA-diagnosis are in general positive for each disease and for all risk groups
considered: an increase in the number of couples choosing for (further) offspring, an increase in
births of healthy children and a decrease in the number of affected children. On the negative side
an increase is expected in the number of affected pregnancies that may be terminated. The
availability of DNA-diagnosis also results in an increase in the number of births of healthy
carriers. Furthermore, DNA-diagnosis induces considerable savings in the health care budget
with the exception of the situation where both parents have a prior risk of 1:45 or lower to be
carriers of the CF mutation. The savings increase with the burden of care for a particular disease
and with higher prior risks.
Although the results differ across disease categories they suggest that positive effects and
savings may also be produced in other disease categories where the health care expenditure for
treatment is considerable and where prior risks of affected children are above the level of  about
1%. As DNA-diagnosis appears to be rather cost-effective in the diseases considered here, one
may like to investigate a broader application of this counselling service, e.g. by not only helping
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couples presenting themselves with a request for counselling but though actively searching for
families with high risk profiles (e.g. by testing mentally disabled for fra(X)). In cost-effectiveness
research  of CF-screening there are indications that a program for CF screening leads to savings
[21].
On the basis of the results reported here the Health Insurance Executive was informed that the
current Dutch practice of genetic counselling is a rather cost-effective health care intervention.
The board subsequently decided to incorporate this activity into the package of health care
services available to all publicly insured in the Netherlands.
12
Acknowledgements
We thank the health insurance Executive Board Committee DNA-analysis who coached us
during the study and the experts for their valuable information about DNA-diagnosis and
genetic counselling. We are especially grateful to Prof.dr. C.H.C.M Buys for his helpful
remarks on a draft version of this paper.
References
[1] Hille E, Kroon M de. Epidemiologie van infertiliteit. Institute for MTA.
Erasmus University Rotterdam 1992.
[2] Gezondheidsraad. Advies inzake planningsregeling klinische genetica. s' Gravenhage:
Gezondheidsraad, 1992.
[3] Emery AEH, Reaburn JA, Skinner R, Holloway S, Lewis P. Prospective study of genetic
counselling. Br Med J 1979;1:1253-1256.
[4] Sorenson JR, Scotch JP, Swazey JP, Wertz DC, Heeren TC. Reproductive plans of genetic
counseling clients not eligible for prenatal diagnosis. Am J Med Genet 1987;28:345-352.
[5] Frets PG. The reproductive decision after genetic counseling. Dissertation at the
Erasmus University Rotterdam, Rotterdam, 1990.
[6] Dankert-Roelse JE. Effects of neonatal screening for cystic fibrosis. Dissertation  at the
University of Groningen, 1988.
[7] Kaback M, Zippin D, Boyd P, Cantor R. Attitudes toward prenatal diagnosis of cystic
fibrosis among parents of affected children. In: Lawson 1994: Cystic fibrosis horizons.
[8] Leonard CO, Chase GA, Childs B. Genetic counseling: a consumers view. New Engl J
Med 1972;287:433-439.
[9] Tybkjaer HW. Behavioural changes in CF families' reproductive pattern after
introduction of prenatal diagnosis. Unpublished paper 1992. Danish CF Association.
[10] Kloosterman MD. Prenatale diagnostiek, enige cijfers over de laatste jaren. Ned Tijdschr
Obstetrie & Gynaecologie 1990;103:238-242.
[11] Brandenburg H. Prenatal diagnosis in women of advanced maternal age. Dissertation  at the
Erasmus University Rotterdam, Rotterdam, 1992.
[12] Beekhuis JR, Mantingh A, De Wolf BTHM, Van Lith JMM, Breed ASPM.
Serumscreening van zwangeren op foetale neurale-buisdefecten en Down syndroom; eerste
ervaringen in Nederland. Ned Tijdschr Geneeskd 1993;137:1303-1307.
[13] World health organization. Advisory Group on Hereditary Diseases. Community
approaches to the control of hereditary diseases. Unpublished WHO document
HMG/WG/85.4,1985.
[14] Wildhagen MF, Verhey JBGM, Hinderink HBM, Kooij L, Tijmstra T, Ten Kate LP,
Gerritsen J, Bakker W, Habbema JFD. Cost of care of patients with cystic fibrosis in
the Netherlands in 1990-1991. Thorax 1996;51:298-301.
[15] Halley DJJ, van den Ouweland AMW, Van der Hout AH, Scheffer H. Overzicht van 5 
jaar DNA-diagnostiek voor cysitische fyfrose. LOD Nieuwsbrief 1995; 2:8-10.
[16] Höweler CJ. A clinical and genetic study in myotonic dystrophy. Dissertation at the
Erasmus University Rotterdam, Rotterdam, 1986.
[17] Harper PS. Myotonic dystrophy, second edition. Saunders: London, 1989.
[18] Brunner HG, Nillesen W, Van Oost BA, et al. Presymptomatic diagnosis of myotonic
dystrophy. J Med Genet 1992;29:780-784
[19] Oostra BA, Jacky PB, Brown WT, Rousseau F. Guidelines for the diagnosis of fragile X
syndrome. J Med Genet 1993;30:410-413.
Turner AM, Robinson H, Wake S, et al. Counselling risk figures for fragile X carrier 
females of varying band sizes for use in predicting the likelihood of retardation in their
offspring. Am J Genet 1994; 51: 458-462.
[21] Van de Laar J, Ten Kate LP. Preconceptionele screening op dragerschap voor 
cystische fibrose. Toetsing aan de Gezondheidsraad-criteria voor genetische screening.
Ned Tijdschr Geneekd 1996;9:487-491

Table 1: Assumptions about reproductive decisions of couples at risk (ranges used in sensitivity analyslis)
Interventions % at risk couples choosing risk affected child
>10% a)
risk affected child
<10% b)
No form of carrier or
prenatal diagnosis available
(further) offspring 50% c)
CF 30% d)
(30%-70%)
80% e)
carrier screening 100% f) 90% g)
(60%-100%)
(further) offspring 85% h)
(60%-100%)
prenatal diagnosis 90% i)
(60%-100%)
DNA-diagnosis available
termination of pregnancy
when the fetus is affected
99% j)
Risk of an affected child>10% when a couple already has an affected child or when carrier
screening gives an unfavourable testresult
Prior risk of an affected child <10% when a couple is related to an affected child
Emery et al,1979[3]; Sorenson et al, 1987 [4]; Frets, 1990 [5]
Average of: Dankert-Roelse, 1988 [6]; Kaback et al, 1984 [7]; Leonard et al, 1972 [8]
Average of: Sorenson et al, 1987 [4]; Frets, 1990 [5]
Diagnosis to confirm that a parent is a carrier of disease after the birth of an affected child
Pers. comm. with genetic clinicians of four clinical centres in Groningen, Leiden, Rotterdam and
Nijmegen
Frets, 1990 [5]
Tybkjaer, 1992 [9]; Pers. comm. with genetic clinicians of four clinical centres in Groningen, Leiden,
Rotterdam and Nijmegen
Kloosterman, 1990 [10]; Brandenburg, 1992 [11]; Beekhuis et al, 1993 [12]
Table 2: Cost estimates used in the model in DFL 1994(exchange rate US$
Baseline estimate Ranges sensitivity analysis
DNA test 1,200 500 - 2,500
Delivery 3,916
Abortion (13 weeks) 987
Curettment 668
Life time cost of cystic fibrosis 1)
Discounted with 5%
1,319,284
545,968
250,000 - 2,500,000
Life time cost of Duchenne muscular disease 2)
Discounted with 5%
747, 173
487,723
250,000 - 2,500,000
Life time cost of cong. myotonic dystrophia 2)
Discounted with 5%
1,187,919
424,635
250,000 - 2,500,000
Life time cost of fragile X syndrome 2)
Discounted with 5%
4,107,920
820,017
250,000 - 2,500,000
1) Study Group Costs and Effects of CF carrier screening, 1994. iMGZ, Erasmus University Rotterdam
2) Global burden of illness studies by study group costs and effects of DNA diagnosis, 1994. iMTA, Erasmus University Rotterdam
Table 3: Effects of "DNA-diagnosis" versus "pedigree analysis" in distinct risk groups
Disease + prior risks Effects of DNA-diagnosis for 100 consulting couples
prior risk of parents being carriers (af-
fected child)
couples getting pregnant healthy children affected children terminated pregnancies
CF 1 (1:4) + 55.0 + 40.7 -  5.2 + 19.5
CF 1:45 (1:180) + 17.8 + 17.7 -  0.2 +  0.3
CF 1:60 (1:240) + 17.8 + 17.8 -  0.2 +  0.2
CF 1:120 (1:480) + 17.9 + 17.9 -  0.1 +  0.1
DMD 1 (1:2) + 35.0 + 25.6 - 10.2 + 19.6
DMD 2:3 (1:3) + 40.0 + 38.3 -  7.3 +  9.0
DMD 1:3 (1:6) + 41.0 + 41.7 -  2.8 +  2.0
DMD 1:6 (1:12) + 16.0 + 18.0 -  2.6 +  0.6
CMD 1 (1:2) + 35.0 + 17.1 - 20.4 + 38.3
CMD 1 (1:3) + 32,9 + 10.1 -  8.3 + 31
FraX 1 (45%) + 35.0 + 25.9 -  7.9 + 17
FraX 1:2 (22.5% + 38.9 + 38.4 -  3.0 +  3.4
Table 4: Effects of DNA-diagnosis versus pedigree analysis in distributed risk groups
Disease Effects of DNA-diagnosis for 100 consulting couples
Cystic fibrosis (a) +
+
-
+
38
30
3
11
couples choosing (further) offspring
healthy children
affected children
terminated pregnancies
Duchenne muscular disease (b) +
+
-
+
33
31
6
8
couples choosing (further) offspring
healthy children
affected children
terminated pregnancies
Myotonic dysthropy (c) +
+
-
+
34
14
15
35
couples choosing (further) offspring
healthy children
affected children
terminated pregnancies
Fragile X syndrome (d) +
+
-
+
37
32
5
10
couples choosing (further) offspring
healthy children
affected children
terminated pregnancies
Percentages of couples with different prior risks of an affected child
a) (55% 1:4) (15% 1:180) (15% 1:240) (15% 1:480)
b) (25% 1:2)(25% 1:3) (25% 1:6) (25% 1:12)
c) (50% 1:2)(50% 1:3)
d) (50% 0.45)(50% 0.225)
Table 5: Additional (+) costs or savings (-) of DNA-diagnosis versus pedigree analysis per consulting couple in DFL
Disease Prior risk of parents being carriers
(prior risk of affected child)
Costs minus savings for one consulting
couple
Cystic fibrosis 1(1:4) - 62,621
Cystic fibrosis 1:45 (1:180) + 42
Cystic fibrosis 1:60 (1:240) + 854
Cystic fibrosis 1:120 (1:480) + 2,075
Duchenne muscular dystrophy 1 (1:2) - 71,751
Duchenne muscular dystrophy 2:3 (1:3) - 50,200
Duchenne muscular dystrophy 1:3 (1:6) - 16,956
Duchenne muscular dystrophy 1:6 (1:12) - 16,254
Myotonic dystrophy 1 (1:2) - 226,347
Myotonic dystrophy 1 (1:3) - 90,223
Fragile X syndrome 1 (±45%) - 321,417
Fragile X syndrome 1:2 (±22.5%) - 118,034
Table 6: Results sensitivity analysis: Effects DNA-diagnosis versus pedigree analysis for 100 consulting couples in distributed risk groups
Disease % couples getting pregnant with only pedigree analysis (variation 30%-
70%)
risk of affected child >10%
% couples choosing (DNA) prenatal diagnosis
(variation 60% -100%)
30% 70% 60% 100%
Cystic
fibrosis
+38
+30
-    3
+11
- 34,000
+16
+14
-   8
+11
-107,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
+38
+30
+  1
+  7
+12,000
+38
+30
-    4
+12
-  49,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
Duchenne
muscular
dystrophy
+48
+43
-   3
+ 8
- 20,000
+19
+19
-   8
+ 8
- 58,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
+33
+31
-    3
+  5
-  21,000
+33
+31
-    7
+  9
-  45,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
Myotonic
dystrophy
+53
+25
-   6
+35
- 68,000
+15
+  3
-  22
+35
-250,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
+34
+14
-    3
+23
-  30,000
+34
+14
-  18
+39
- 201,000
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
Fragile X
syndrome
+56
+48
-   3
+10
- 107,729
+18
+16
-   9
+10
-347,467
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
+37
+32
-    2
+  7
-  79,680
+37
+32
-    7
+11
- 266,443
couples getting pregnant
healthy children
affected children
terminated pregnancies
cost - savings per couple in DFL
